ALZHEIMER'S IMMUNOTHERAPY IN A PRIMATE MODEL OF CEREBRAL AMYLOID ANGIOPATHY

脑淀粉样血管病灵长类动物模型中的阿尔茨海默病免疫治疗

• 批准号: 7562657
• 负责人: LARY C WALKER
• 金额: $ 3.95万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7562657
• 关键词: Age; Alzheimer' s Disease; Amyloidosis; Antibody Formation; Blood Vessels; Cerebral Amyloid Angiopathy; Clinical; Computer Retrieval of Information on Scientific Projects Database; Development; Funding; Grant; Human; Immunization; Immunotherapy; Institution; Modeling; Primates; Proteins; Research; Research Personnel; Resources; Safety; Saimiri; Source; Testing; United States National Institutes of Health; Week

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is investigating the effects of A¿-immunization in the squirrel monkey, a species that develops significant vascular ¿-amyloidosis with age. We have shown that short-term immunization of older squirrel monkeys against the A¿ protein, which is critical to the development of Alzheimer's disease, is safe and is able to induce significant antibody formation. There is also pathological evidence of limited vasculopathy after 11 weeks of immunization, confirming that squirrel monkeys are a good model for testing the safety and efficacy of immunotherapy for Alzheimer's disease. The present study has begun long-term immunization to more closely mimic human clinical use of immunization therapy.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 该项目正在研究 Aβ-免疫对松鼠猴的影响，松鼠猴是一种随着年龄的增长而出现明显的血管β-淀粉样变性的物种。我们已经证明，对老年松鼠猴进行短期免疫以对抗 A¿ 蛋白（这对于阿尔茨海默氏病的发展至关重要）是安全的，并且能够诱导显着的抗体形成。还有病理学证据表明免疫11周后出现有限的血管病变，证实松鼠猴是测试阿尔茨海默病免疫疗法安全性和有效性的良好模型。本研究已开始长期免疫，以更接近地模拟人类临床使用的免疫治疗。